Develops antibodies for asthma and COPD.
Jun 2026Revenue $2.95M/yrExpenses $73.4M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Connect Biopharma Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.95M and expenses $73.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $64.0K | $58.1M | −$58.1M |
| Dec 2024 | $26.0M | $48.5M | −$22.5M |
| Dec 2023 | $0.00 | $69.1M | −$69.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.